Your browser doesn't support javascript.
loading
Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia, Rohit R; Abe, Dreaux; Wong, Daniel; Singla, Nirmish; Savelyeva, Anna; Chertack, Nathan; Woldu, Solomon L; Lotan, Yair; Mauck, Ryan; Ouyang, Dan; Meng, Xiaosong; Lewis, Cheryl M; Majmudar, Kuntal; Jia, Liwei; Kapur, Payal; Xu, Lin; Frazier, A Lindsay; Margulis, Vitaly; Strand, Douglas W; Coleman, Nicholas; Murray, Matthew J; Amatruda, James F; Lafin, John T; Bagrodia, Aditya.
Afiliação
  • Badia RR; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Abe D; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Wong D; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Singla N; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Savelyeva A; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Chertack N; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Woldu SL; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Mauck R; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Ouyang D; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Meng X; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Lewis CM; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Majmudar K; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Jia L; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Kapur P; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Xu L; Quantitative Biomedical Research Center, Department of Population & Data Sciences, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Frazier AL; Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Boston, Massachusetts.
  • Margulis V; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Strand DW; Department of Urology, I.M. Sechenov First Moscow State University.
  • Coleman N; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Murray MJ; Department of Pathology, University of Cambridge, UK.
  • Amatruda JF; Department of Pathology, University of Cambridge, UK.
  • Lafin JT; Department of Pediatric Hematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Bagrodia A; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Departments of Pediatrics and Medicine, Keck School of Medicine, University of Southern California.
J Urol ; 205(1): 137-144, 2021 Jan.
Article em En | MEDLINE | ID: mdl-32856980
ABSTRACT

PURPOSE:

Current serum tumor markers for testicular germ cell tumor are limited by low sensitivity. Growing evidence supports the use of circulating miR-371a-3p as a superior marker for malignant (viable) germ cell tumor management. We evaluated the real-world application of serum miR-371a-3p levels in detecting viable germ cell tumor among patients undergoing partial or radical orchiectomy. MATERIALS AND

METHODS:

Serum samples were collected from 69 consecutive patients before orchiectomy. Performance characteristics of serum miR-371a-3p were compared with conventional serum tumor markers (⍺-fetoprotein/ß-human chorionic gonadotropin/lactate dehydrogenase) between patients with viable germ cell tumor and those without viable germ cell tumor on orchiectomy pathology. Relative miR-371a-3p levels were correlated with clinical course. The Kruskal-Wallis test and linear and ordinal regression models were used for analysis.

RESULTS:

For detecting viable germ cell tumor, combined conventional serum tumor markers had a specificity of 100%, sensitivity of 58% and AUC of 0.79. The miR-371a-3p test showed a specificity of 100%, sensitivity of 93% and AUC of 0.978. Median relative expression of miR-371a-3p in viable germ cell tumor cases was more than 6,800-fold higher than in those lacking viable germ cell tumor. miR-371a-3p levels correlated with composite stage (p=0.006) and, among composite stage I cases, independently associated with embryonal carcinoma percentage (p=0.0012) and tumor diameter (p <0.0001). Six patients underwent orchiectomy after chemotherapy and were correctly predicted to have presence or absence of viable germ cell tumor by the miR-371a-3p test.

CONCLUSIONS:

If validated, the miR-371a-3p test can be used in conjunction with conventional serum tumor markers to aid clinical decision making. A positive miR-371a-3p test in patients after preoperative chemotherapy or with solitary testes could potentially guide subsequent orchiectomy or observation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Orquiectomia / Biomarcadores Tumorais / Neoplasias Embrionárias de Células Germinativas / MicroRNAs / MicroRNA Circulante Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Orquiectomia / Biomarcadores Tumorais / Neoplasias Embrionárias de Células Germinativas / MicroRNAs / MicroRNA Circulante Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article